Exploring the nucleotide molecular mechanism of compound kushen injection for lung adenocarcinoma based on network pharmacology and molecular docking

Zhangpeng Ye, Xin Yao, Zhubei Chen, Qin Jin, Qingsheng YouFrontiers in Oncology 2022 · DOI

TL;DR

This study leverages network pharmacology and molecular docking to unravel the complex molecular mechanisms of Compound Kushen Injection (CKI), a traditional Chinese medicine, in treating lung adenocarcinoma. By identifying key compounds, target genes, and pathways, the research provides a theoretical foundation for CKI's therapeutic potential and its impact on patient survival.

What Problem Does This Paper Address?

Lung adenocarcinoma (LUAD) is a leading cause of cancer-related deaths globally. While conventional treatments like surgery, chemotherapy, and radiotherapy exist, they often come with significant side effects. Traditional Chinese Medicine (TCM), like Compound Kushen Injection (CKI), has shown promise in cancer treatment, but its precise molecular mechanisms, especially concerning LUAD prognosis and survival, remain largely unelucidated. This paper aims to bridge this knowledge gap by systematically investigating CKI's potential therapeutic targets and pathways in LUAD using computational approaches.

Methods

The researchers employed a multi-pronged computational strategy:

  • Network Pharmacology (NP): This approach was central to the study. It involved:
  • Component and Target Screening: Identifying active compounds from CKI (specifically from kushen and baituling) and their associated target genes using databases like TCMSP. Criteria for active ingredients included oral bioavailability (OB) ≥30% and drug-likeness (DL) ≥0.18.
  • LUAD Gene Identification: Gathering genes related to lung adenocarcinoma from various public databases (OMIM, PharmGkb, GeneCards, TTD, DrugBank).
  • Gene Intersection: Identifying common genes between CKI targets and LUAD-related genes.
  • Network Construction: Building a protein-protein interaction (PPI) network for the intersected genes and a drug-component-gene regulatory network.
  • Core Gene/Component Identification: Screening for key nodes (genes and compounds) within these networks based on network topology parameters (degree, betweenness, closeness, etc.).
  • Functional and Pathway Enrichment Analysis: Using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses to understand the biological functions and pathways associated with the identified target genes.
  • Survival Analysis: Analyzing clinical data from The Cancer Genome Atlas (TCGA) to identify genes associated with LUAD prognosis and survival, and then intersecting these with CKI's target genes.
  • Molecular Docking: Performing molecular docking simulations to predict the binding affinity between identified key compounds from CKI and their potential target proteins, validating the predicted interactions.

Datasets

The study utilized several public databases for data acquisition:

  • Traditional Chinese Medicine Pharmacology (TCMSP): For screening active ingredients and target genes of kushen and baituling.
  • UniProt: For gene symbol verification.
  • Online Mendelian Inheritance in Man (OMIM), Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGkb), GeneCards, Target Database (TTD), and DrugBank: For identifying lung adenocarcinoma-related genes.
  • The Cancer Genome Atlas (TCGA): For clinical information on LUAD prognosis and survival.
  • STRING database: For constructing protein-protein interaction networks.
  • PubChem: For obtaining ligand 2D structures for molecular docking.

No new benchmarks were introduced; the study relied on existing public datasets.

Key Insights and Ideas

  • Multi-target, Multi-pathway Action: CKI doesn't appear to act on a single target but rather influences LUAD through a complex network of multiple compounds interacting with numerous genes and pathways. This aligns with the holistic nature of TCM.
  • Prognostic Significance of Identified Genes: The study identified specific genes (e.g., BCL2, BIRC5, CCNA2, CDK1, PRKCB, RXRA, RXRB, STAT1) that are not only targeted by CKI but also significantly associated with LUAD patient survival. This suggests CKI's therapeutic effect is directly linked to modulating these prognostic factors.
  • Key Pathways Implicated: The enrichment analysis pointed towards CKI's influence on critical pathways like PI3K-Akt signaling, TNF signaling, and pathways related to non-small cell lung cancer and Hepatitis C. These pathways are known to be involved in cancer progression, survival, and response to treatment.
  • Molecular Docking Validation: The molecular docking results provided strong evidence for the binding affinity between CKI's active compounds and their predicted protein targets, lending credibility to the network pharmacology findings.

Key Results

  • 35 Key Compounds and 4 Central Target Genes: The study identified 35 active compounds from CKI and four potential central target genes that are crucial for its therapeutic effect in LUAD.
  • Eight Prognostic Genes Identified: Through the intersection of CKI targets and prognostic genes, eight key genes (BCL2, BIRC5, CCNA2, CDK1, PRKCB, RXRA, RXRB, and STAT1) were highlighted as important mediators of CKI's effect on LUAD survival.
  • Survival Improvement: Batch survival analysis indicated that CKI could potentially improve the survival and prognosis of LUAD patients by regulating these identified genes.
  • Good Docking Affinity: Key compounds from CKI demonstrated good docking affinity with their respective target proteins, suggesting effective molecular interactions.

Limitations and Future Work

  • Computational Nature: The study is primarily based on computational analysis and public databases. The authors acknowledge that further experimental validation is crucial to confirm these findings in vitro and in vivo.
  • Specificity of CKI: While the study focused on LUAD, it suggests that further research is needed to determine if CKI has a more significant effect on specific subtypes of lung cancer compared to others.
  • Experimental Validation: The authors explicitly state that additional experiments are required to confirm the proposed mechanisms and therapeutic targets. This includes in vitro assays and in vivo studies to validate the role of identified compounds and pathways in LUAD treatment.
  • Clinical Application: The study aims to promote the further clinical application of CKI and provide a theoretical basis for future experimental studies, implying a need for clinical trials to translate these findings into practice.

Summary updated

Abstract

Compound kushen injection is an effective traditional Chinese medicine for the treatment of lung cancer. However, its influence on the survival and prognosis of patients with lung adenocarcinoma patients was less studied; especially its pharmacological mechanism remains to be further elucidated. In the present study, we adopted a network pharmacology (NP)-based approach to screening effective compounds, screening and predicting target genes, analyzing biological functions and pathways, constructing a regulatory network and protein interaction network, and screening the key targets. Moreover, mass survival analysis and molecular docking were conducted. In the end, 35 key compounds and four possible central target genes were screened out, which could be used for the treatment of lung adenocarcinoma and affected the survival and prognosis of patients with lung adenocarcinoma. In addition, their key compounds had good docking affinity. Enrichment analysis showed that CKI might affect the treatment and prognosis of lung adenocarcinoma patients by regulating the PI3K-Akt signaling pathway, TNF signaling pathway, non-small cell lung cancer, Hepatitis C, etc. We discussed the pharmacological mechanisms and potential therapeutic targets of CKI in the treatment of lung adenocarcinoma, which verified the effect of CKI on the prognosis and survival of patients. The present study might promote the further clinical application of CKI and provide a theoretical basis for further experimental studies.
BibTeX
@inproceedings{ye2022exploring,
  author = {Zhangpeng Ye and Xin Yao and Zhubei Chen and Qin Jin and Qingsheng You},
  title = {{Exploring the nucleotide molecular mechanism of compound kushen injection for lung adenocarcinoma based on network pharmacology and molecular docking}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.1013052},
}
Figure